argenx Shares Fall 0.35% as $280M Trading Volume Ranks 383rd in U.S. Market Amid Cautious Sentiment

On September 18, 2025, , , . equities. The biopharmaceutical company’s shares experienced muted demand amid mixed sector performance.

Analysts noted that recent updates for argenx’s core pipeline failed to generate significant momentum, tempering investor enthusiasm. While the company’s efgartigimod program remains a strategic focus, market participants appeared cautious ahead of upcoming regulatory decisions. Additionally, broader market volatility in healthcare stocks contributed to a risk-off sentiment, impacting smaller-cap disproportionately.

To run this back-test rigorously I first need to pin down a few practical details. Please let me know your preferences on the following so I can configure the test correctly: 1. Universe • Should the ranking of “top-500 by daily trading volume” be taken from all U.S. listed stocks, or from a specific universe (e.g., S&P 500 constituents, Nasdaq only, NYSE + Nasdaq, etc.)? • Are ADRs, ETFs, SPACs, or penny stocks (price < $1) allowed, or should we filter them out? 2. Weighting & rebalancing • Do you want the 500 names held equally-weighted each day (standard approach), or weighted by another rule (e.g., volume-proportional)? • The strategy description implies daily turnover (buy at today’s close, sell at tomorrow’s close). Is that correct? 3. Trading frictions • Should we apply transaction costs or slippage? If yes, what cost per trade (e.g., 5 bp per side) should I assume? 4. Benchmark (optional) • Would you like the results compared against a benchmark such as SPY, or is absolute performance sufficient? Once I have this information I can generate the data-retrieval plan and run the back-test.